The IVF Add-Ons Debate: Which Extras Have Evidence Behind Them?

Nearly three-quarters of IVF patients report using at least one add-on during treatment. That number comes from HFEA patient survey data. Here’s what’s striking: according to the UK’s Human Fertilisation and Embryology Authority (HFEA), not a single add-on they’ve reviewed has earned a “green” rating, the category reserved for treatments with robust evidence of effectiveness. That gap between what patients are choosing and what the evidence supports is what this article is about.

Below, we break down the most common IVF add-ons, what the evidence actually says about each, and how to have a more informed conversation with your clinic.

IVF add-ons are optional extras offered on top of standard in vitro fertilization: tests, supplements, or procedures designed to improve your chances of success. Your clinic might offer them. Your Facebook group swears by them. And yes, they come with an extra bill.

The HFEA rates add-ons using a five-category system: Green (evidence of effectiveness), Yellow (conflicting evidence), Grey (insufficient evidence to rate), Black (no effect), and Red (may reduce effectiveness or pose safety concerns). The system was overhauled recently to offer more nuance. Other professional bodies have weighed in too. In 2025, an Italian fertility group (SIFES-MR) issued guidance on 28 add-ons, and the European Society of Human Reproduction and Embryology (ESHRE) reviewed 27 add-ons with similar caution.

Why are add-ons so common? Part of it is business: clinics offer them, and there’s always a market. But the bigger part is human. You’re vulnerable during fertility treatment. You want every possible edge. And the line between evidence-based medicine and hope can blur in a way that marketing is happy to exploit.

PGT-A screens embryos for chromosomal abnormalities before transfer. The logic is intuitive: transfer only the chromosomally normal embryos, reduce miscarriage risk, and improve your odds.

The case for: Chromosomal abnormalities are a leading cause of miscarriage and implantation failure. For patients with recurrent implantation failure or significant age-related concerns, PGT-A may identify viable embryos that would otherwise be overlooked. A review in PMC noted potential benefits in select patient populations.

The case against: Three randomized controlled trials plus recent SART data show that PGT-A doesn’t significantly improve live birth rates for most patients. It adds $3,000 to $6,000 or more per cycle. There’s also an ongoing debate about whether biopsy damages embryos or misses mosaicism, where only some cells carry abnormalities. The scientific consensus remains split.

ERA is a biopsy-based test that analyzes the timing of your “implantation window,” the days your uterine lining is most receptive to an embryo. It was initially heralded as a way to personalize transfer timing.

More recent studies have found that ERA doesn’t improve outcomes and may even be detrimental to pregnancy rates. Multiple reproductive medicine organizations have moved away from recommending it. If your clinic suggests it, ask specifically what evidence they’re relying on for your situation.

EmbryoGlue is a transfer medium containing hyaluronate, designed to make it easier for the embryo to implant. According to the HFEA’s assessment, a meta-analysis of 26 randomized controlled trials found a modest benefit for fresh embryo transfers, roughly a 5 percent improvement in pregnancy rates. The catch: no benefit with frozen transfers, and a possible increase in multiple pregnancies, which carry their own health risks.

This is one of the more promising add-ons, but it still doesn’t earn a green rating. The benefit, while measurable, is modest and context-dependent.

Time-lapse systems continuously monitor embryo development, using software to predict which embryos are most likely to implant. The concept sounds compelling.

The largest international trial, conducted by Queen Mary University of London, found no advantage over conventional methods. ESHRE now advises against using it to improve outcomes. Yet many clinics still promote it, often at significant cost.

This procedure thins the shell around the embryo, theoretically making implantation easier. The evidence is limited. It may help patients over 37 or those with prior IVF failure, but for most patients, it’s not recommended as routine practice.

Intravenous fat emulsions or immune-modulating therapies are sometimes offered to patients with suspected immune dysfunction. These lack good-quality research and can have serious side effects, including infusion reactions. The HFEA does not recommend routine use.

Cost is the obvious reason. Add-ons can push a single cycle from $12,000 to $22,000 or higher. That’s a significant difference for most families.

But there’s a subtler financial argument, one the HFEA has highlighted: for most patients, paying for an additional proven IVF cycle may be more effective than adding unproven extras to a single cycle. If your clinic is recommending $5,000 in add-ons that may not work, sometimes another cycle of standard-of-care IVF is the better investment.

Then there’s the emotional cost. In fertility forums, the conversation around add-ons often comes down to a single question: “Will I regret not trying it?” It’s a question born of compassion for yourself. But it’s also the perfect setup for marketing. Every add-on becomes something you can’t afford not to try. That’s a heavy weight to carry when the add-on doesn’t change the outcome.

The most robust predictor of IVF success isn’t an add-on. It’s the fundamentals: good embryo culture, an experienced lab, and a clinic that follows evidence-based protocols.

There’s another category that deserves attention: physiological readiness. Dr. Alice Domar, a Harvard psychologist and pioneer in mind-body medicine for fertility, published research showing that patients in mind-body programs had pregnancy rates above 50 percent, compared to 20 percent in control groups. That’s not a traditional add-on; it’s a shift in how you prepare your body and mind for treatment, and it costs far less than most extras.

One emerging area with clinical data behind it is physiological readiness monitoring. OTO Fertility offers a daily 3-to-5-minute biosensor assessment that generates a Fertility Readiness Score with personalized recommendations. In clinical studies, patients whose metrics reached the “Fertility Zone” had conception rates up to 85 percent. It’s not a traditional IVF add-on, but a way to understand and optimize your body’s readiness before and during treatment, complementing your protocol rather than replacing it.

Questions to ask your clinic about any add-on:

The add-ons conversation is evolving. More trials are underway. Rating systems like the HFEA’s are becoming more granular, moving beyond broad judgments to patient-specific guidance. And patients, like you, are asking better, harder questions of their clinics.

The goal isn’t to reject everything new. It’s to bring the same rigor to these decisions that you’d bring to any other major investment in your health. You deserve a clinic that explains not just what they offer, but why. And you deserve the freedom to choose without shame, regardless of what you decide.

HFEA Treatment Add-Ons — Independent ratings and explanations for each add-on, from the UK’s fertility regulator.

HFEA Fertility Sector Report 2024–25 — National data on treatment outcomes and patient satisfaction.

PMC Add-Ons Efficacy Review — Comprehensive scientific review of add-on evidence and future directions.

SIFES-MR 2025 Guidance — Italian fertility group’s assessment of 28 IVF add-ons.

ESHRE Recommendations — European Society of Human Reproduction and Embryology guidance on 27 add-ons.

Queen Mary Time-Lapse Trial — The largest international study on time-lapse imaging in IVF.

Domar Mind-Body Research — Foundational research on stress reduction and fertility outcomes.

OTO Fertility — Physiological readiness monitoring for fertility treatment.

Fertility Out Loud: IVF Add-Ons Guide — Patient-friendly overview of add-ons and decision-making.